Wednesday, January 30, 2019
The new treatment was developed by the pharmaceutical laboratory for accelerated evolutionary biotechnology under the direction of the CEO, Dr. Ilan Morad, according to the report.
"We believe that we will offer a complete cancer medicine for one year," said Dan Aridor, chairman of the company's board. "Our cancer drugs will be effective from the first day, they will last for several weeks and will have minimal or no side effects at a much lower price than most other treatments on the market."
The treatment, called "MuTaTo," will use a combination of anticancer peptides and toxins that specifically kill cancer cells.
The treatment will eventually be personalized and patients will be given a specific cocktail of drugs according to their kind of cancer, Morard told the newspaper.
Despite the importance of the announcement, some voices doubt the functioning of the new treatment, for example it has been tested only in mice.
In this regard, the deputy director of the National Cancer Association of the United States, Len Liechtenfeld, said on the blog of the agency that "it is understood that we all share the hope of being right".
"Unfortunately, we must be aware that this is far from an effective treatment for people with cancer, and even less for a cure," he said.
Finally, the expert noted that Israeli researchers did not publicly display the collected data to support his statement, despite failing to disclose evidence that the treatment was successful in mice, saying that so far all this was an interview with local media published by site publimetro.cl.
With information from Chronicle.